Evercore Has Lowered Expectations for Baxter International (NYSE:BAX) Stock Price

Baxter International (NYSE:BAX) had its price objective decreased by equities research analysts at Evercore from $23.00 to $22.00 in a report released on Monday,MarketScreener reports. The brokerage presently has an “outperform” rating on the medical instruments supplier’s stock. Evercore’s price objective points to a potential upside of 32.39% from the stock’s current price.

A number of other brokerages also recently issued reports on BAX. Zacks Research raised Baxter International from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Weiss Ratings reissued a “sell (d)” rating on shares of Baxter International in a research report on Wednesday, January 21st. Jefferies Financial Group reduced their price target on Baxter International from $21.00 to $19.00 and set a “hold” rating on the stock in a research report on Friday, February 13th. Wells Fargo & Company reduced their price target on Baxter International from $21.00 to $19.00 and set an “equal weight” rating on the stock in a research report on Friday, December 12th. Finally, Barclays reduced their price target on Baxter International from $30.00 to $25.00 and set an “overweight” rating on the stock in a research report on Friday, February 13th. Two investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $19.80.

Baxter International Price Performance

Shares of NYSE BAX opened at $16.62 on Monday. The firm has a market cap of $8.58 billion, a P/E ratio of -8.98, a price-to-earnings-growth ratio of 1.18 and a beta of 0.62. The company has a current ratio of 2.31, a quick ratio of 1.56 and a debt-to-equity ratio of 1.55. Baxter International has a 1-year low of $15.73 and a 1-year high of $32.68. The business’s 50 day moving average is $18.87 and its 200-day moving average is $19.71.

Baxter International (NYSE:BAX) last announced its earnings results on Thursday, February 12th. The medical instruments supplier reported $0.44 earnings per share for the quarter, missing analysts’ consensus estimates of $0.53 by ($0.09). The firm had revenue of $2.97 billion for the quarter, compared to the consensus estimate of $2.82 billion. Baxter International had a positive return on equity of 16.95% and a negative net margin of 8.51%.Baxter International’s revenue for the quarter was up 8.0% on a year-over-year basis. During the same quarter last year, the business posted $0.58 EPS. Baxter International has set its FY 2026 guidance at 1.850-2.050 EPS. Equities research analysts predict that Baxter International will post 2.48 earnings per share for the current year.

Institutional Investors Weigh In On Baxter International

A number of large investors have recently modified their holdings of the business. Basepoint Wealth LLC acquired a new stake in shares of Baxter International during the 4th quarter valued at $26,000. CoreFirst Bank & Trust acquired a new stake in shares of Baxter International during the 2nd quarter valued at $27,000. Imprint Wealth LLC acquired a new stake in shares of Baxter International during the 3rd quarter valued at $27,000. CYBER HORNET ETFs LLC acquired a new stake in shares of Baxter International during the 2nd quarter valued at $40,000. Finally, MUFG Securities EMEA plc acquired a new stake in shares of Baxter International during the 2nd quarter valued at $46,000. Institutional investors and hedge funds own 90.19% of the company’s stock.

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.